CN102834388B - Cgrp受体拮抗剂 - Google Patents

Cgrp受体拮抗剂 Download PDF

Info

Publication number
CN102834388B
CN102834388B CN201180016888.2A CN201180016888A CN102834388B CN 102834388 B CN102834388 B CN 102834388B CN 201180016888 A CN201180016888 A CN 201180016888A CN 102834388 B CN102834388 B CN 102834388B
Authority
CN
China
Prior art keywords
compound
cgrp
pharmaceutically acceptable
methyl
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180016888.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN102834388A (zh
Inventor
P.V.查特维度拉
G.M.杜博奇克
J.E.马科
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43896902&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102834388(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN102834388A publication Critical patent/CN102834388A/zh
Application granted granted Critical
Publication of CN102834388B publication Critical patent/CN102834388B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201180016888.2A 2010-03-30 2011-03-11 Cgrp受体拮抗剂 Active CN102834388B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31901510P 2010-03-30 2010-03-30
US61/319,015 2010-03-30
PCT/US2011/028168 WO2011123232A1 (en) 2010-03-30 2011-03-11 Cgrp receptor antagonist

Publications (2)

Publication Number Publication Date
CN102834388A CN102834388A (zh) 2012-12-19
CN102834388B true CN102834388B (zh) 2014-07-16

Family

ID=43896902

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180016888.2A Active CN102834388B (zh) 2010-03-30 2011-03-11 Cgrp受体拮抗剂

Country Status (29)

Country Link
US (1) US8481546B2 (cg-RX-API-DMAC10.html)
EP (1) EP2552906B1 (cg-RX-API-DMAC10.html)
JP (1) JP5908455B2 (cg-RX-API-DMAC10.html)
KR (3) KR20180049168A (cg-RX-API-DMAC10.html)
CN (1) CN102834388B (cg-RX-API-DMAC10.html)
AR (1) AR080746A1 (cg-RX-API-DMAC10.html)
AU (1) AU2011233627B2 (cg-RX-API-DMAC10.html)
BR (1) BR112012024785B1 (cg-RX-API-DMAC10.html)
CA (1) CA2794950C (cg-RX-API-DMAC10.html)
CL (1) CL2012002739A1 (cg-RX-API-DMAC10.html)
CY (1) CY1117593T1 (cg-RX-API-DMAC10.html)
DK (1) DK2552906T3 (cg-RX-API-DMAC10.html)
EA (1) EA022815B1 (cg-RX-API-DMAC10.html)
ES (1) ES2562610T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20160287T1 (cg-RX-API-DMAC10.html)
HU (1) HUE028735T2 (cg-RX-API-DMAC10.html)
IL (1) IL221665A (cg-RX-API-DMAC10.html)
MX (1) MX2012010725A (cg-RX-API-DMAC10.html)
NZ (1) NZ603231A (cg-RX-API-DMAC10.html)
PE (1) PE20130340A1 (cg-RX-API-DMAC10.html)
PL (1) PL2552906T3 (cg-RX-API-DMAC10.html)
PT (1) PT2552906E (cg-RX-API-DMAC10.html)
RS (1) RS54608B1 (cg-RX-API-DMAC10.html)
SG (1) SG183918A1 (cg-RX-API-DMAC10.html)
SI (1) SI2552906T1 (cg-RX-API-DMAC10.html)
SM (1) SMT201600078B (cg-RX-API-DMAC10.html)
TW (1) TWI483937B (cg-RX-API-DMAC10.html)
WO (1) WO2011123232A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201207292B (cg-RX-API-DMAC10.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024222889A1 (zh) 2023-04-28 2024-10-31 成都思倍博医药科技有限公司 含氧代吡啶并脂肪环或脂杂环结构的化合物及其医药用途
WO2025061141A1 (zh) 2023-09-21 2025-03-27 成都思倍博医药科技有限公司 具有改善的药代动力学特性的药物组合物

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519194D0 (en) * 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists
GB201519195D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201707938D0 (en) 2017-05-17 2017-06-28 Univ Sheffield Compounds
WO2020077038A1 (en) * 2018-10-13 2020-04-16 Biohaven Pharmaceutical Holding Company Ltd. Prodrugs of cgrp antagonists
KR20210116560A (ko) * 2019-01-20 2021-09-27 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. 편두통 돌발을 치료하기 위한 cgrp 길항제
SG11202111251SA (en) 2019-04-11 2021-11-29 R P Scherer Technologies Llc Formulation for oral delivery of proteins, peptides and small molecules with poor permeability
CN114980862A (zh) * 2019-12-17 2022-08-30 拜尔哈文制药股份有限公司 Cgrp抑制剂的鼻内药物组合物
CN116456981A (zh) * 2020-11-19 2023-07-18 辉瑞爱尔兰制药公司 用于改善的grp抑制剂递送的组合物
CA3202137A1 (en) * 2020-11-19 2022-05-27 Pfizer Ireland Pharmaceuticals Compositions for improved delivery of cgrp inhibitors
JP2024509165A (ja) 2021-03-02 2024-02-29 シージーアールピー ダイアグノスティクス ゲーエムベーハー 片頭痛の治療及び/又は発生の低減
WO2022217008A1 (en) 2021-04-09 2022-10-13 Teva Czech Industries S.R.O Solid state forms of zavegepant and process for preparation thereof
WO2023026205A1 (en) 2021-08-24 2023-03-02 Cgrp Diagnostics Gmbh Preventative treatment of migraine
US20240366618A1 (en) * 2021-10-11 2024-11-07 Pfizer Ireland Pharmaceuticals CGRP Antagonists for Treating Trigeminal Neuralgia
WO2024046223A1 (zh) * 2022-08-30 2024-03-07 熙源安健医药(上海)有限公司 吲唑甲酰胺类衍生物及其制备方法和用途
US20250276959A1 (en) 2022-11-09 2025-09-04 Teva Czech Industries S.R.O. Solid state forms of zavegepant hydrochloride and process for preparation thereof
CN116003387B (zh) * 2022-11-20 2024-03-26 药康众拓(北京)医药科技有限公司 一种氘代吲唑丙酰胺类化合物、药物组合物和用途
WO2025003905A1 (en) 2023-06-29 2025-01-02 Pfizer Inc. Solid forms of (r)-n-(3-(7-methyl-1h-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)piperazin-1-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide
CN119462607B (zh) * 2023-08-10 2025-11-28 南京宁丹新药技术股份有限公司 一类喹啉酮衍生物及其用途
CN117551081A (zh) * 2023-11-13 2024-02-13 北京康立生医药技术开发有限公司 一种偏头痛治疗药物新的制备方法
ES3027457A1 (es) * 2023-12-13 2025-06-13 Moehs Iberica Sl Metodo de preparacion de zavegepant, intermedios de sintesis de zavegepant y metodos de preparacion de los mismos
IT202400011158A1 (it) 2024-05-16 2025-11-16 Olon Spa Processo per preparare (r)-2-ammino-3-(7-metil-1h-indazol-5-il) propanoato di metile, e suo uso come intermedio per la sintesi di zavegepant.
WO2026033478A1 (en) 2024-08-09 2026-02-12 Olon S.P.A. Process for preparing 3-piperidin-4-il-1h- quinolin-2-one or a salt thereof and its use as an intermediate for the preparation of pharmaceutical active ingredients antagonists of the cgrp peptide receptor
CN119306698B (zh) * 2024-10-09 2025-10-21 浙江工业大学 一种制备扎维吉泮中间体的新方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1671711A (zh) * 2002-06-05 2005-09-21 布里斯托尔-迈尔斯斯奎布公司 降钙素基因相关肽受体拮抗剂
CN101495480A (zh) * 2006-05-03 2009-07-29 百时美施贵宝公司 作为降钙素基因相关肽受体拮抗剂的受限化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
EP1722792A1 (de) 2004-03-03 2006-11-22 Boehringer Ingelheim International GmbH Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
US7834007B2 (en) 2005-08-25 2010-11-16 Bristol-Myers Squibb Company CGRP antagonists
WO2010006168A2 (en) 2008-07-09 2010-01-14 University Of Rochester Methods of treating cancer using and agent that modulates activity of the calcitonin-gene related peptide ("cgrp") receptor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1671711A (zh) * 2002-06-05 2005-09-21 布里斯托尔-迈尔斯斯奎布公司 降钙素基因相关肽受体拮抗剂
CN101495480A (zh) * 2006-05-03 2009-07-29 百时美施贵宝公司 作为降钙素基因相关肽受体拮抗剂的受限化合物

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024222889A1 (zh) 2023-04-28 2024-10-31 成都思倍博医药科技有限公司 含氧代吡啶并脂肪环或脂杂环结构的化合物及其医药用途
EP4703362A1 (en) 2023-04-28 2026-03-04 Chengdu Sibeibo Pharmaceutical Technology Co., Ltd Compound containing oxo-pyrido-aliphatic ring or aliphatic heterocyclic structure, and medical use thereof
WO2025061141A1 (zh) 2023-09-21 2025-03-27 成都思倍博医药科技有限公司 具有改善的药代动力学特性的药物组合物

Also Published As

Publication number Publication date
US20120059017A1 (en) 2012-03-08
ZA201207292B (en) 2014-03-26
CA2794950C (en) 2017-09-26
HUE028735T2 (en) 2017-01-30
KR20180049168A (ko) 2018-05-10
TW201139414A (en) 2011-11-16
SI2552906T1 (sl) 2016-05-31
HK1174914A1 (zh) 2013-06-21
US8481546B2 (en) 2013-07-09
ES2562610T3 (es) 2016-03-07
AR080746A1 (es) 2012-05-02
KR101854249B1 (ko) 2018-05-03
CL2012002739A1 (es) 2013-03-22
SG183918A1 (en) 2012-10-30
WO2011123232A1 (en) 2011-10-06
IL221665A (en) 2016-07-31
PL2552906T3 (pl) 2016-06-30
TWI483937B (zh) 2015-05-11
AU2011233627A1 (en) 2012-11-15
KR20130076807A (ko) 2013-07-08
BR112012024785A2 (pt) 2016-06-07
BR112012024785A8 (pt) 2017-10-17
AU2011233627B2 (en) 2013-09-12
SMT201600078B (it) 2016-04-29
MX2012010725A (es) 2012-10-05
HRP20160287T1 (hr) 2016-04-08
JP5908455B2 (ja) 2016-04-26
EA201270751A1 (ru) 2013-02-28
BR112012024785B1 (pt) 2020-12-01
PT2552906E (pt) 2016-03-18
EP2552906B1 (en) 2016-01-06
KR20170068615A (ko) 2017-06-19
NZ603231A (en) 2014-02-28
RS54608B1 (sr) 2016-08-31
CA2794950A1 (en) 2011-10-06
CY1117593T1 (el) 2017-06-28
KR101747477B1 (ko) 2017-06-14
CN102834388A (zh) 2012-12-19
PE20130340A1 (es) 2013-03-30
EP2552906A1 (en) 2013-02-06
JP2013523733A (ja) 2013-06-17
DK2552906T3 (en) 2016-03-29
EA022815B1 (ru) 2016-03-31

Similar Documents

Publication Publication Date Title
US8481546B2 (en) CGRP receptor antagonist
JP7397452B2 (ja) ヘテロアリールカルボキシアミド化合物
EP2086531A1 (en) Compositions and treatments comprising 5-lipoxygenase-activating protein inhibitors and nitric oxide modulators
EP4076395A1 (en) Intranasal pharmaceutical compositions of cgrp inhibitors
US9695176B2 (en) Substituted imidazo[1,5-a]pyrazines as CGRP receptor antagonists
WO2018222917A1 (en) Ire1 small molecule inhibitors
US10392367B2 (en) IRE1 small molecule inhibitors
CN113880772B (zh) 一类cdk激酶抑制剂及其应用
JP4245682B2 (ja) キノリン誘導体、イソキノリン誘導体、およびシンノリン誘導体、並びに抗炎症剤および抗アレルギー剤
CN116514798A (zh) 一种可抑制宫颈癌增殖的化合物及其制备方法与应用
US9745342B2 (en) NMDA receptor modulators and prodrugs, salts, and uses thereof
HK1174914B (en) Cgrp receptor antagonist
US20040191312A1 (en) 5-HT3 receptor agonists as neuroprotectors
WO2025003905A1 (en) Solid forms of (r)-n-(3-(7-methyl-1h-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)piperazin-1-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide
TW202416975A (zh) 萘并呋喃取代的戊二醯亞胺類化合物的晶型、製備方法及其應用
JP2006328057A (ja) 抗不安薬及びそのスクリーニング方法
TW200403239A (en) Novel compounds

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant